A recent ruling by judges from the U.S. Court of Appeals for the Federal Circuit makes it more likely that Sandoz soon may be able to start selling a biosimilar that treats cancer patients.

But beyond this practical result, there are many more far-reaching consequences from the ruling in Amgen v. Sandoz.